CAV1抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-6: Human fetal muscle tissue, Human fetal lung tissue, Human leiomyosarcoma tissue, mouse lung, Mouse heart tissue, NIH/3T3 cells, Primary antibody: P04673(CAV1 Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P04673(CAV1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P04673(CAV1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

Caveolin-1 (CAV1) is a key structural and regulatory protein involved in forming caveolae, specialized plasma membrane invaginations that participate in cellular processes such as signal transduction, endocytosis, and lipid homeostasis. As a scaffolding protein, CAV1 interacts with various signaling molecules (e.g., G-proteins, receptor tyrosine kinases) to modulate pathways like EGFR, MAPK, and nitric oxide signaling. CAV1 antibodies are essential tools for detecting this protein in research, aiding in studies of its roles in cancer, cardiovascular diseases, and metabolic disorders.

In cancer, CAV1 exhibits dual roles, acting as a tumor suppressor in some contexts (e.g., inhibiting oncogenic signaling) or promoting metastasis in others. Its dysregulation is linked to prostate, breast, and lung cancers. In cardiovascular and metabolic diseases, CAV1 influences endothelial function, atherosclerosis, and insulin sensitivity. CAV1 antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess expression levels, localization, and interactions in tissues or cell lines.

Discrepancies in CAV1-associated findings across studies highlight context-dependent roles, possibly due to tissue-specific isoforms or post-translational modifications. Research using CAV1 antibodies continues to clarify its complex involvement in fibrosis, neurodegeneration, and infection mechanisms, making it a focal point for therapeutic targeting.